These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9643490)

  • 41. [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea].
    Kim CW; Lee BI; Kim BW; Kim JI; Park SH; Kim JK; Han SW; Jung IS; Sun HS; Lee AW; Lee KY
    Korean J Gastroenterol; 2005 Sep; 46(3):189-95. PubMed ID: 16179838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
    Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
    Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.
    Hall PA; Woodman AC; Campbell SJ; Shepherd NA
    Gut; 2001 Nov; 49(5):618-23. PubMed ID: 11600462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.
    Ten Kate FJC; Nieboer D; Ten Kate FJW; Doukas M; Bruno MJ; Spaander MCW; Looijenga LHJ; Biermann K;
    Am J Surg Pathol; 2018 Jul; 42(7):918-926. PubMed ID: 29697438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
    Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
    J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of advanced endoscopic imaging on Barrett's esophagus in daily clinical practice.
    Beg S; Mensa M; Fullard M; Finerty E; Richman P; Leahy A
    Gastrointest Endosc; 2018 May; 87(5):1189-1194. PubMed ID: 28958906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
    Redston M; Noffsinger A; Kim A; Akarca FG; Rara M; Stapleton D; Nowden L; Lash R; Bass AJ; Stachler MD
    Gastroenterology; 2022 Feb; 162(2):468-481. PubMed ID: 34757142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
    Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
    Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autofluorescence endoscopy for detection of high-grade dysplasia in short-segment Barrett's esophagus.
    Niepsuj K; Niepsuj G; Cebula W; Zieleźnik W; Adamek M; Sielańczyk A; Adamczyk J; Kurek J; Sieroń A
    Gastrointest Endosc; 2003 Nov; 58(5):715-9. PubMed ID: 14595307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Barrett's esophagus.
    Ertan A; Younes M
    Dig Dis Sci; 2000 Aug; 45(8):1670-3. PubMed ID: 11007123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus.
    Ragunath K; Krasner N; Raman VS; Haqqani MT; Cheung WY
    Endoscopy; 2003 Dec; 35(12):998-1003. PubMed ID: 14648410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.
    Eisen GM; Montgomery EA; Azumi N; Hartmann DP; Bhargava P; Lippman M; Benjamin SB
    Gastrointest Endosc; 1999 Dec; 50(6):814-8. PubMed ID: 10570342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment.
    Panjehpour M; Coppola D; Overholt BF; Vo-Dinh T; Overholt S
    Anticancer Res; 2008; 28(1B):485-9. PubMed ID: 18383889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.